The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
The accompanying notes are
an integral part of the unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
(UNAUDITED)
Note 1 — Organization and Business Operations
Pacifico Acquisition Corp. (the “Company”)
is a newly organized blank check company incorporated as a Delaware corporation on March 2, 2021. The Company was formed for the purpose
of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more
businesses or entities (the “Business Combination”). The Company is an early stage and emerging growth company and, as such,
the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of June 30,2022, the Company had not yet commenced
any operations and had not generated revenue. All activities through June 30,2022 relate to the Company’s formation and the initial
public offering (the “IPO”) described below. The Company has selected December 31 as its fiscal year end.
The Company’s sponsor is Pacifico Capital
LLC, a Delaware limited liability company (the “Sponsor”).
On April 5, 2022, Pacifico entered into a Merger Agreement (the “Merger
Agreement”), by and among Caravelle International Group, a Cayman Islands exempted company (“PubCo”) and a wholly-owned
subsidiary of the Company, Pacifico International Group, a Cayman Islands exempted company and a direct wholly-owned subsidiary of PubCo
(“Merger Sub 1”), Pacifico Merger Sub 2 Inc., a Delaware corporation and a direct wholly-owned subsidiary of PubCo (“Merger
Sub 2” and, together with PubCo and Merger Sub 1, each, individually, an “Acquisition Entity” and, collectively, the
“Acquisition Entities”), and Caravelle Group Co., Ltd, a Cayman Islands exempted company (“Caravelle”), pursuant
to which (a) Merger Sub 1 will merge with and into Caravelle (the “Initial Merger”), and Caravelle will be the surviving corporation
of the Initial Merger and a direct wholly owned subsidiary of PubCo, and (b) following confirmation of the effectiveness of the Initial
Merger, Merger Sub 2 will merge with and into Pacifico (the “SPAC Merger” and together with the Initial Merger, the “Merger”),
and Pacifico will be the surviving corporation of the SPAC Merger and a direct wholly owned subsidiary of PubCo (collectively, the “Business
Combination”). Following the Business Combination, PubCo will be a publicly traded holding company listed on a national stock exchange
in the United States. These entities had not commenced any operations as of June 30, 2022. The board of directors of Pacifico has unanimously
approved the Merger Agreement.
On May 13, 2022, the draft registration statement
on Form F-4 was submitted with the SEC regarding the proposed Merger between Pacifico and Caravelle.
On July 18, 2022, the Amendment No. 1 to the draft
registration statement was submitted to address comments received from the SEC regarding the draft registration statement.
Financing
The registration statement for the Company’s
IPO (as described in Note 3) was declared effective on September 13, 2021. On September 16, 2021, the Company consummated the IPO of 5,000,000
units at $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the IPO, the
Company sold to its Sponsor and Chardan Capital Markets LLC (“Chardan”) (and/or their designees) 281,250 units at $10.00 per
unit (the “Private Units”) in a private placement generating total gross proceeds of $2,812,500, which is described in Note
4.
The Company granted the underwriters a 45-day
option to purchase up to 750,000 Units to cover Over-allotment, if any. As of September 22, 2021, the underwriters had fully exercised
the option and purchased 750,000 additional Units (the “Over-allotment Units”), generating gross proceeds of $7,500,000.
Upon the closing of the Over-allotment on September
22, 2021, the Company consummated the Private Placement sale of an additional 26,250 Private Units to the Sponsor and Chardan at a price
of $10.00 per Private Unit, generating gross proceeds of $262,500.
Offering costs amounted to $4,759,144 consisting
of $1,437,500 of underwriting fees, $2,469,769 of deferred underwriting fees and $851,875 of other offering costs (including $320,994
of the estimated cost of Unit Purchase Option issued to the underwriter). The Company received net proceeds of $58,075,000 from the IPO
(including the Over-allotment Units) and the sale of Private Units.
Trust Account
Upon the closing of the IPO and the private placement
(including Over-allotment), a total of $58,075,000 was placed in a trust account (the “Trust Account”) with American Stock
Transfer & Trust Company, LLC acting as trustee.
The funds held in the Trust Account can be invested
in United States government treasury bills, notes or bonds having a maturity of 185 days or less or in money market funds meeting the
applicable conditions under Rule 2a-7 promulgated under the Investment Company Act of 1940, as amended, until the earlier of the consummation
of its first business combination and the Company’s failure to consummate a business combination within applicable period of time.
Placing funds in the Trust account may not protect
those funds from third party claims against the Company. Although the Company will seek to have all vendors, service providers, prospective
target businesses or other entities it engages, execute agreements with the Company waiving any claim of any kind in or to any monies
held in the Trust Account, there is no guarantee that such persons will execute such agreements.
In addition, interest income earned on the funds
in the Trust account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred
by the Company may be paid prior to a business combination only from the net proceeds of the IPO and private placement not held in the
Trust Account.
Business Combination
Pursuant to NASDAQ listing rules, the Company’s
initial business combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80%
of the value of the funds in the Trust account (excluding any taxes payable on the income earned on the Trust account), which the Company
refers to as the 80% test, at the time of the execution of a definitive agreement for its initial business combination, although the Company
may structure a business combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust
account balance. If the Company is no longer listed on NASDAQ, it will not be required to satisfy the 80% test.
The Company currently anticipates structuring
a business combination to acquire 100% of the equity interests or assets of the target business or businesses. The Company may, however,
structure a business combination where the Company merges directly with the target business or where the Company acquires less than 100%
of such interests or assets of the target business in order to meet certain objectives of the target management team or shareholders or
for other reasons, but the Company will only complete such business combination if the post-transaction company owns 50% or more of the
outstanding voting securities of the target or otherwise owns a controlling interest in the target sufficient for it not to be required
to register as an investment company under the Investment Company Act. If less than 100% of the equity interests or assets of a target
business or businesses are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned
or acquired is what will be valued for purposes of the 80% test.
The Company will provide its holders of the outstanding
Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the
completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or
(ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct
a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion
of the amount then in the Trust Account (initially anticipated to be $10.10 per Public Share, plus any pro rata interest earned on the
funds held in the Trust Account and not previously released to the Company to pay its franchise and income tax obligations). The Company
will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business
Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination.
If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons,
the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”),
conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and
file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction
is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem
shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules.
Additionally, each public stockholder may elect
to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder
approval in connection with a Sponsor and any of the Company’s officers or directors that may hold Insider Shares (as defined in
Note 5) (the “Initial Stockholders”) and Chardan have agreed (a) to vote their Insider Shares, Private Shares (as defined
in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and (b) not to convert
any shares (including the Insider Shares) in connection with a stockholder vote to approve, or sell the shares to the Company in any tender
offer in connection with, a proposed Business Combination.
If the Company seeks stockholder approval of a
Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation
provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is
acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the
Public Shares, without the prior consent of the Company.
The Company will have until 12 months from the
closing of the IPO to consummate a Business Combination. On April 5, 2022, the Company entered into a merger agreement with Caravelle
International Group. In addition, if the Company anticipates that it may not be able to consummate initial business combination within
12 months, the Company’s insiders or their affiliates may, but are not obligated to, extend the period of time to consummate a business
combination two times by an additional three months each time (for a total of 15 or 18 months to complete a business combination) (the
“Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor
or its affiliate or designees must deposit into the Trust Account $500,000, or $575,000 if the underwriters’ over-allotment option
is exercised in full ($0.10 per Public Share in either case), for each such extension on or prior to the date of the applicable deadline.
Liquidation
If the Company is unable to complete a Business
Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as
promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable,
and less certain amount of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption
will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions,
if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval
of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case
to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
The Initial Stockholders and Chardan have agreed
to waive their liquidation rights with respect to the Insider Shares and Private Shares if the Company fails to complete a Business Combination
within the Combination Period. However, if the Initial Stockholders or Chardan acquires Public Shares in or after the IPO, such Public
Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within
the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held
in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event,
such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public
Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution
will be less than the IPO price per Unit ($10.00).
In order to protect the amounts held in the Trust
Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products
sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce
the amount of funds in the Trust Account to below $10.10 per Public Share, except as to any claims by a third party who executed a valid
and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held
in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities,
including liabilities under the Securities Act of 1933, as amended. Moreover, in the event that an executed waiver is deemed to be unenforceable
against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims.
Risks and Uncertainties
In March 2020, the World Health Organization declared the outbreak
of a novel coronavirus (“COVID-19”) as a pandemic which continues to spread throughout the United States and the world. As
of the date the financial statements were issued, there was considerable uncertainty around the expected duration of this pandemic. Management
continues to evaluate the impact of the COVID-19 pandemic and the Company has concluded that while it is reasonably possible that COVID-19
could have a negative effect on completing the Proposed Public Offering and subsequently identifying a target company for a Business Combination,
the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
Going Concern
As of June 30, 2022, the Company had $41,949 of
cash held outside its Trust Account for use as working capital. If the estimated costs of identifying a target business, undertaking in-depth
due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient
funds available to operate its business prior to its Business Combination. Moreover, the Company may need to obtain additional financing
either to complete its Business Combination or because it becomes obligated to redeem a significant number of public shares upon consummation
of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business
Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with
the completion of our Business Combination. If the Company is unable to complete its Business Combination because it does not have sufficient
funds available, it will be forced to cease operations and liquidate the Trust Account.
In connection with the Company’s assessment
of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures
of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that if the Company
is unable to complete a Business Combination within 12 months from the closing of the IPO, then the Company will cease all operations
except for the purpose of liquidating. The date for liquidation and subsequent dissolution raise substantial doubt about the Company’s
ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company
be required to liquidate.
Note 2 — Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements
are presented in U.S. Dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”)
and pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed consolidated financial statements include the
accounts of the Company and its wholly owned subsidiaries as outlined in Note 1 (PubCo, Merger Sub 1 and Merger Sub 2) where the
Company has the ability to exercise control. All significant intercompany balances and transactions have been eliminated in consolidation.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting
of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows
for the periods presented.
The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, as filed with
the SEC on March 31, 2022. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the
results to be expected for the year ending December 31, 2022 or for any future periods.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS
Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public
accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote
on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth
company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
The preparation of financial statements in conformity
with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near
term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents
as of June 30,2022.
Offering Costs Associated with the IPO
Offering costs consist of underwriting, legal,
accounting, registration and other expenses incurred through the balance sheet date that are directly related to the IPO. Offering costs
amounted to $4,759,144 consisting of $1,437,500 of underwriting fees, $2,469,769 of deferred underwriting fees and $851,875 of other offering
costs (including $320,994 of the estimated cost of Unit Purchase Option issued to the underwriter). The Company complies with the requirements
of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A – “Expenses of Offering”. The Company allocates
offering costs between public shares and public rights based on the estimated fair values of public shares and public rights at the date
of issuance. Accordingly, $4,372,914 was allocated to public shares and was charged to temporary equity, and $386,230 was allocated to
public rights and was charged to stockholders’ equity.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage of $250,000. The Company has not experienced losses on such account as of June 30, 2022.
Cash and Investments Held in Trust Account
The Company’s portfolio of investments held
in the Trust Account is comprised of investments in money market funds that invest in U.S. government securities. The Company’s
investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair
value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account
are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations.
The estimated fair value of investments held in the Trust Account are determined using available market information. Trust Account activities
included interest income of $82,491 for the six months ended June 30, 2022.
Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject
to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing
Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at
fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that is either within the control
of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified
as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features
certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future
events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the
stockholders’ equity section of the Company’s balance sheet.
The Company has made a policy election in accordance with ASC 480-10-S99-3A
and recognizes changes in redemption value in additional paid-in capital (or accumulated deficit in the absence of additional paid-in
capital) over an expected 12-month period leading up to a Business Combination.
At June 30,2022, the amount of common stock subject
to possible redemption reflected in the balance sheet are reconciled in the following table:
Gross proceeds | |
$ | 57,500,000 | |
Less: | |
| | |
Proceeds allocated to public rights | |
| (4,197,500 | ) |
Allocation of offering costs related to redeemable shares | |
| (4,372,914 | ) |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 6,754,904 | |
Common stock subject to possible redemption | |
$ | 55,684,490 | |
Net Income (Loss) per Share
The Company complies with accounting and disclosure
requirements of FASB ASC 260, Earnings Per Share. The condensed statements of operations include a presentation of income (loss) per redeemable
share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income
(loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss)
allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net
loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number
of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the
common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of June 30,2022, the Company
did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then
share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented.
The net income (loss) per share presented in the
condensed statement of operations is based on the following:
| |
For the three | | |
For the six | |
| |
months | | |
months | |
| |
ended | | |
ended | |
| |
June 30, | | |
June 30, | |
| |
2022 | | |
2022 | |
Net Loss | |
$ | (184,160 | ) | |
$ | (372,264 | ) |
Accretion of common stock to redemption value | |
| (2,442,912 | ) | |
| (4,357,666 | ) |
Net loss including accretion of common stock to redemption value | |
$ | (2,627,072 | ) | |
$ | (4,729,930 | ) |
| |
For the three months ended | |
| |
June 30, 2022 | |
| |
| | |
Non- | |
| |
Redeemable | | |
redeemable | |
| |
shares | | |
shares | |
Basic and diluted net income/(loss) per share: | |
| | |
| |
Numerators: | |
| | |
| |
Allocation of net loss including accretion of common stock | |
$ | (2,015,432 | ) | |
$ | (611,640 | ) |
Accretion of common stock to redemption value | |
| 2,442,912 | | |
| — | |
Allocation of net income (loss) | |
$ | 427,480 | | |
$ | (611,640 | ) |
| |
| | | |
| | |
Denominators: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 5,750,000 | | |
| 1,745,000 | |
Basic and diluted net income/(loss) per share | |
$ | 0.07 | | |
$ | (0.35 | ) |
| |
For the six months ended | |
| |
June 30, 2022 | |
| |
| | |
Non- | |
| |
Redeemable | | |
redeemable | |
| |
shares | | |
shares | |
Basic and diluted net income/(loss) per share: | |
| | |
| |
Numerators: | |
| | |
| |
Allocation of net loss including accretion of common stock | |
$ | (3,628,699 | ) | |
$ | (1,101,231 | ) |
Accretion of common stock to redemption value | |
| 4,357,666 | | |
| — | |
Allocation of net income (loss) | |
$ | 728,967 | | |
$ | (1,101,231 | ) |
| |
| | | |
| | |
Denominators: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 5,750,000 | | |
| 1,745,000 | |
Basic and diluted net income/(loss) per share | |
$ | 0.13 | | |
$ | (0.63 | ) |
Income Taxes
The Company follows the asset and liability method
of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized
tax benefits and no amounts accrued for interest and penalties as of June 30,2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax
examinations by major taxing authorities since inception.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities, which qualify as financial instruments under ASC 825, “Financial Instrument,” approximates the carrying
amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Recent Accounting Standards
In August 2020, the FASB issued ASU No. 2020-06,
“Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU
2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception
and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning
after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial
statements.
Note 3 — Initial Public Offering
On September 16, 2021, the Company sold 5,000,000
Units at a price of $10.00 per Unit, generating gross proceeds of $50,000,000 related to its IPO. Each Unit consists of one share of common
stock and one right (“Public Right”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon
the consummation of a Business Combination (see Note 7). The Company granted the underwriters a 45-day option to purchase up to 750,000
Units to cover Over-allotment, if any. On September 22, 2021, the underwriters fully exercised the option and purchased 750,000 additional
Units (the “Over-allotment Units”), generating gross proceeds of $7,500,000.
The Company incurred total costs of $4,759,144
consisting of $1,437,500 of underwriting fees, $2,469,769 of deferred underwriting fees (payable only upon completion of a Business Combination)
and $851,875 of other offering costs (including $320,994 of the estimated cost of Unit Purchase Option issued to the underwriter).
Note 4 — Private Placement
Concurrently with the closing of the IPO, the
Company’s Sponsor and Chardan (and/or their designees) purchased an aggregate of 281,250 Private Units at a price of $10.00 per
Private Unit for an aggregate purchase price of $2,812,500 in a private placement. Upon the closing of the Over-allotment on September
22, 2021, the Company consummated the Private Placement sale of an additional 26,250 Private Units to the Sponsor and Chardan at a price
of $10.00 per Private Unit, generating gross proceeds of $262,500.
The Private Units are identical to the Public
Units except with respect to certain registration rights and transfer restrictions. The proceeds from the Private Units were added to
the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination
Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements
of applicable law), and the Private Units and all underlying securities will expire worthless.
Note 5 — Related Party Transactions
Promissory Note - Related Party
On March 15, 2021, the Sponsor loaned the Company
an aggregate of up to $200,000 to cover expenses related to the IPO pursuant to a promissory note (the “Promissory Note”).
The Promissory Note is unsecured, interest-free and due on the closing of the IPO. As of June 30, 2022, the Company fully repaid the Promissory
Note and no amount is owed under the note.
On April 14, 2022, the Sponsor loaned the Company
an additional $150,000 pursuant to a promissory note (the “Note”). The Note is unsecured, interest-free and due after the
date on which the Company consummates an initial business combination. The Sponsor has the right to convert the Note into Private Units
at $10.00 per unit.
Insider Shares
On April 13, 2021, the Company issued 1,437,500
shares of common stock to the Initial Stockholders (the “Insider Shares”) for an aggregate of $25,000. The Insider Shares
include an aggregate of up to 187,500 shares subject to forfeiture by the Initial Stockholders to the extent that the underwriters’
over-allotment is not exercised in full, so that the Initial Stockholders will collectively own 20% of the Company’s issued and
outstanding shares after the IPO (assuming the Initial Stockholders do not purchase any Public Shares in the IPO and excluding the Private
Units). As the over-allotment option was fully exercised on September 22, 2021, no portion of the Insider Shares are subject to forfeiture.
The Initial Stockholders have agreed, subject
to certain limited exceptions, not to transfer, assign or sell any of their Insider Shares until, with respect to 50% of the Insider Shares,
the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common stock
equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for
any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the
Insider Shares, until the six months after the consummation of a Business Combination, or earlier, in either case, if, subsequent to a
Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of
the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property.
Note 6 — Commitments and contingency
Registration Rights
The holders of the Insider Shares, Private Units
(and all underlying securities), and any shares that may be issued upon conversion of working capital loans (may be provided by the Company’s
insiders, officers, directors, or their affiliates to finance transaction costs in connection with searching for a target business or
consummating a Business Combination) will be entitled to registration rights pursuant to a registration rights agreement to be signed
prior to or on the effective date of IPO. The holders of the majority of these securities are entitled to make up to two demands that
the Company register such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights
at any time commencing three months prior to the date on which the Insider Shares are to be released from escrow. The holders of a majority
of the Private Units and units issued in payment of working capital loans made to the Company can elect to exercise these registration
rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain
“piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business
Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The underwriters were paid a cash underwriting
discount of 2.5% of the gross proceeds of the IPO, or $1,437,500 including Over-allotment. In addition, the underwriters will be entitled
to a deferred fee of 3.75% of the gross proceeds of the IPO, or $2,156,250, which will be paid upon the closing of a Business Combination
from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. The underwriters will also be entitled
to 43,125 common shares, to be issued if the Company closes a Business Combination.
Unit Purchase Option
The Company sold to Chardan (and/or its designees),
for $100, an option (“UPO”) to purchase 158,125 units as the over-allotment option was fully exercised on September 22, 2021.
The UPO will be exercisable at any time, in whole or in part, between the close of the IPO and fifth anniversary of the effective date
of the registration at a price per Unit equal to $11.50 (or 115% of the volume weighted average trading price of the ordinary shares
during the 20 trading day period starting on the trading day immediately prior to consummation of an initial Business Combination). The
option and the underlying securities that may be issued upon exercise of the option, have been deemed compensation by FINRA and are therefore
subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA’s NASDAQ Conduct Rules. Additionally, the option may not
be sold, transferred, assigned, pledged or hypothecated for a one-year period (including the foregoing 180-day period) following the
date of IPO except to any underwriter and selected dealer participating in the IPO and their bona fide officers or partners.
Right of First Refusal
The Company has granted Chardan a right of first
refusal, for a period of 15 months after the date of the consummation of a Business Combination, to act as lead underwriters or minimally
as a co-manager, with at least 30% of the economics; or, in the case of a three-handed deal 20% of the economics, for any and all future
public or private equity and debt offerings.
Professional Fees
The Company has engaged a merger and acquisition
advisor and capital market advisor in connection with business combination to provide services such as introducing the Company to potential
investors that are interested in purchasing the Company’s securities in connection with the initial business combination, assisting
the Company in negotiating the terms and conditions with the target company. The Company will pay the advisor a cash fee or in shares
in a total amount of approximately $4.625 million. In addition, the Company has committed to pay additional $50,000 professional fees
upon the closing of a business combination.
Note 7 — Stockholders’ Equity
Common Stock — The Company
is authorized to issue 10,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the common stock are entitled
to one vote for each share. As of June 30, 2022, there were 1,745,000 shares of common stock (excluding 5,750,000 shares subject to possible
redemption).
Rights — Except in cases
where the Company is not the surviving company in a Business Combination, each holder of a Public Right will automatically receive one-tenth
(1/10) of one share of common stock upon consummation of a Business Combination, even if the holder of a Public Right converted all shares
held by him, her or it in connection with a Business Combination or an amendment to the Company’s Amended and Restated Certificate
of Incorporation with respect to its pre-business combination activities. In the event that the Company will not be the surviving company
upon completion of a Business Combination, each holder of a Public Right will be required to affirmatively convert his, her or its rights
in order to receive the one-tenth (1/10) of a share underlying each Public Right upon consummation of the Business Combination. No additional
consideration will be required to be paid by a holder of Public Rights in order to receive his, her or its additional shares of common
stock upon consummation of a Business Combination. The shares issuable upon exchange of the rights will be freely tradable (except to
the extent held by affiliates of the Company).
The Company will not issue fractional shares
in connection with an exchange of Public Rights. Fractional shares will either be rounded down to the nearest whole share or otherwise
addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, the holders of the Public
Rights must hold rights in multiples of 10 in order to receive shares for all of the holders’ rights upon closing of a Business
Combination. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the
funds held in the Trust Account, holders of Public Rights will not receive any of such funds with respect to their Public Rights, nor
will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Rights,
and the Public Rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders
of the Public Rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash
settle the rights. Accordingly, the rights may expire worthless.
Note 8 — Fair Value Measurements
The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and
liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: |
|
Quoted prices in active markets for
identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability
occur with sufficient frequency and volume to provide pricing information on an ongoing basis. |
|
|
|
Level 2: |
|
Observable inputs other than Level 1 inputs.
Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical
assets or liabilities in markets that are not active. |
|
|
|
Level 3: |
|
Unobservable inputs based on our assessment of
the assumptions that market participants would use in pricing the asset or liability. |
The following table presents information about
the Company’s assets that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021 and indicates
the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.
| |
June 30, 2022 | | |
Quoted
Prices in
Active
Markets (Level 1) | | |
Significant
Other
Observable
Inputs (Level 2) | | |
Significant
Other
Unobservable
Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Marketable securities held in trust account | |
| 58,151,659 | | |
| 58,151,659 | | |
| — | | |
| — | |
| |
December 31, 2021 | | |
Quoted
Prices in
Active
Markets (Level 1) | | |
Significant
Other
Observable
Inputs (Level 2) | | |
Significant
Other
Unobservable
Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Marketable securities held in trust account | |
| 58,076,305 | | |
| 58,076,305 | | |
| — | | |
| — | |
Note 9 — Subsequent Events
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to August 12, 2022, the date that the unaudited condensed financial statements were issued.
Other than described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the
unaudited condensed financial statements.
On July 18, 2022, Form S-4A containing Amendment
No. 1 to the Registration Statement was filed to address comments received from the SEC regarding the Registration Statement.
On August 8, 2022, the Company entered into a $100,000 promissory
note with the Sponsor, Pacifico Capital LLC., $25,000 in cash was received on August 12, 2022. The Note is unsecured, interest-free and
due after the date on which the Company consummates an initial business combination. The Sponsor has the right to convert the note into
private units at $10.00 per unit.